411 related articles for article (PubMed ID: 29516641)
1. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Duan W; Jiang X; Zhao L; Li J; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Yang Y; Wang C
J Cell Mol Med; 2018 May; 22(5):2838-2845. PubMed ID: 29516641
[TBL] [Abstract][Full Text] [Related]
2. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Zhan Y; Du L; Wang L; Jiang X; Zhang S; Li J; Yan K; Duan W; Zhao Y; Wang L; Wang Y; Wang C
Mol Cancer; 2018 Sep; 17(1):142. PubMed ID: 30268126
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer.
Zhang S; Du L; Wang L; Jiang X; Zhan Y; Li J; Yan K; Duan W; Zhao Y; Wang L; Wang Y; Shi Y; Wang C
J Cell Mol Med; 2019 Feb; 23(2):1396-1405. PubMed ID: 30467945
[TBL] [Abstract][Full Text] [Related]
4. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
Duan W; Du L; Jiang X; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Zhang X; Pan H; Yang Y; Wang C
Oncotarget; 2016 Nov; 7(48):78850-78858. PubMed ID: 27793008
[TBL] [Abstract][Full Text] [Related]
5. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Jiang X; Duan W; Wang R; Wang L; Zheng G; Yan K; Wang L; Li J; Zhang X; Pan H; Yang Y; Wang C
Oncotarget; 2017 Jun; 8(25):40832-40842. PubMed ID: 28388561
[TBL] [Abstract][Full Text] [Related]
6. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer.
Jiang X; Du L; Wang L; Li J; Liu Y; Zheng G; Qu A; Zhang X; Pan H; Yang Y; Wang C
Int J Cancer; 2015 Feb; 136(4):854-62. PubMed ID: 24961907
[TBL] [Abstract][Full Text] [Related]
7. A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.
Zhang X; Zhang M; Zhang X; Zhu X; Wang J
BMC Med Inform Decis Mak; 2020 Jul; 20(Suppl 3):136. PubMed ID: 32646427
[TBL] [Abstract][Full Text] [Related]
8. Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder.
Li Z; Wang KE; Zhou XL; Zhou J; Ye CH
Med Sci Monit; 2018 Jan; 24():438-447. PubMed ID: 29358570
[TBL] [Abstract][Full Text] [Related]
9. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNAs, ENST00000598996 and ENST00000524265, are correlated with favorable prognosis and act as potential tumor suppressors in bladder cancer.
Shen C; Wang Y; Wu Z; Da L; Gao S; Xie L; Qie Y; Wang Y; Zhang Z; Tian D; Hu H
Oncol Rep; 2020 Nov; 44(5):1831-1850. PubMed ID: 33000254
[TBL] [Abstract][Full Text] [Related]
11. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
12. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
Eissa S; Matboli M; Essawy NO; Kotb YM
Tumour Biol; 2015 Dec; 36(12):9545-52. PubMed ID: 26138586
[TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
Fan CN; Ma L; Liu N
J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
[TBL] [Abstract][Full Text] [Related]
15. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
16. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
17. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
18. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
19. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
[TBL] [Abstract][Full Text] [Related]
20. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
